Mon, Dec 22, 2014, 7:28 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

OncoGenex Pharmaceuticals, Inc. Message Board

  • petruchi0 petruchi0 Feb 2, 2012 8:40 AM Flag

    on the fly

    : Teva's OGX-427 for prostate cancer shows positive results in Phase 2 study
    OncoGenex Pharmaceuticals announced preliminary results from a Phase 2 prostate cancer study with its investigational compound OGX-427, which is designed to inhibit the production of Hsp27. Overexpression of Hsp27 is thought to be an important factor leading to the development of treatment resistance and is associated with negative clinical outcomes in patients with various tumor types. In chemotherapy-naive patients with metastatic castrate-resistant prostate cancer, preliminary study results showed a higher number of patients without disease progression at 12 weeks, and greater declines in prostate-specific antigen and circulating tumor cells with OGX-427 plus prednis one treatment compared to prednisone alone.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
2.09+0.06(+2.96%)Dec 22 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.